ImmunoGen Shares Owned By Insiders vs. Revenue
| IMGNDelisted Stock | USD 18.20 0.81 4.26% |
For ImmunoGen profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ImmunoGen to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ImmunoGen utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ImmunoGen's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ImmunoGen over time as well as its relative position and ranking within its peers.
ImmunoGen |
ImmunoGen Revenue vs. Shares Owned By Insiders Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ImmunoGen's current stock value. Our valuation model uses many indicators to compare ImmunoGen value to that of its competitors to determine the firm's financial worth. ImmunoGen is rated below average in shares owned by insiders category among its peers. It is considered the number one company in revenue category among its peers totaling about 887,697,531 of Revenue per Shares Owned By Insiders. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImmunoGen's earnings, one of the primary drivers of an investment's value.ImmunoGen Revenue vs. Shares Owned By Insiders
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
ImmunoGen |
| = | 0.32 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
ImmunoGen |
| = | 287.61 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
ImmunoGen Revenue vs Competition
ImmunoGen is considered the number one company in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 1.24 Billion. ImmunoGen totals roughly 287.61 Million in revenue claiming about 23% of equities under Health Care industry.
ImmunoGen Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ImmunoGen, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ImmunoGen will eventually generate negative long term returns. The profitability progress is the general direction of ImmunoGen's change in net profit over the period of time. It can combine multiple indicators of ImmunoGen, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies to treat cancer. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Immunogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people.
ImmunoGen Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ImmunoGen. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ImmunoGen position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ImmunoGen's important profitability drivers and their relationship over time.
Use ImmunoGen in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmunoGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunoGen will appreciate offsetting losses from the drop in the long position's value.ImmunoGen Pair Trading
ImmunoGen Pair Trading Analysis
The ability to find closely correlated positions to ImmunoGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ImmunoGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ImmunoGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ImmunoGen to buy it.
The correlation of ImmunoGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ImmunoGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ImmunoGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ImmunoGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ImmunoGen position
In addition to having ImmunoGen in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals Thematic Idea Now
Precious Metals
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Precious Metals theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |